Northwest Biotherapeutics, Inc.
NWBO
$0.2984
$0.01525.37%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -33.83% | 9.60% | 14.57% | 30.76% | 40.40% |
| Total Depreciation and Amortization | 17.95% | 15.94% | 22.37% | 5.40% | 15.53% |
| Total Amortization of Deferred Charges | 4.38% | -25.58% | -14.78% | -4.69% | -14.40% |
| Total Other Non-Cash Items | 43.10% | -60.11% | -63.80% | -70.76% | -79.03% |
| Change in Net Operating Assets | 370.72% | -38.83% | -117.56% | -105.53% | -151.26% |
| Cash from Operations | -6.30% | -18.16% | -24.63% | -7.36% | -1.63% |
| Capital Expenditure | 70.50% | 73.86% | 67.82% | 43.91% | -18.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 70.50% | 73.86% | 67.82% | 43.91% | -18.44% |
| Total Debt Issued | 2.61% | 28.88% | 109.98% | 73.32% | 308.35% |
| Total Debt Repaid | -272.21% | -296.76% | -4.67% | 82.08% | 92.99% |
| Issuance of Common Stock | 817.41% | 328.67% | 45.71% | -79.40% | -91.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -38.48% | -34.15% | -29.68% | -30.97% | -28.80% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -98.95% | -85.24% | -78.70% | 9,400.00% | -- |
| Cash from Financing | 7.63% | 11.20% | 24.36% | 3.22% | 25.71% |
| Foreign Exchange rate Adjustments | 347.61% | -41.17% | 272.35% | -69.31% | -109.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 101.01% | 5.11% | 142.76% | -380.96% | 41.02% |